ModifiedUnitedHealthcarePolicy CS355PA.D

Surgery for the Prevention and Treatment of Lymphedema (for Pennsylvania Only)

This medical policy governs surgical procedures proposed for prevention or treatment of lymphedema for UnitedHealthcare members in Pennsylvania; it addresses coverage stance, definitions, supporting evidence, and applicable procedure codes.

Policy Summary

PayerUnitedHealthcare

PolicySurgery for the Prevention and Treatment of Lymphedema (for Pennsylvania Only)

Policy CodePolicy CS355PA.D

Change TypeUpdated clinical evidence, description of services, and references (material revision)

Effective DateDec 1, 2025

Next Review DateN/A

Key ActionObtain prior authorization in Pennsylvania to confirm medical necessity, document failure of conservative therapy, and ensure procedures are performed at experienced/specialist centers where required.

SourceLink

POLICY UPDATE CHANGES

Updated Description of Services, Clinical Evidence, and References sections to reflect the most current information.

71evidence base size (AAPS review)

69% lowerILR reduced risk

11%-46%overall complication rate

1920Hahn 2025 extremities

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

NNT (ILR vs control)

revision datepolicy history entry

Coverage Criteria — Surgery for Prevention and Treatment of Lymphedema

Not Medically Necessary / Unproven Surgical Treatments

Covered when ALL of the following are met

Not medically necessary stance: Surgical procedures for the prevention or treatment of lymphedema are unproven and not medically necessary due to insufficient evidence of safety and/or efficacy.

Procedures listed include but are not limited to Axillary Reverse Mapping (ARM), Liposuction/Lipectomy, Microsurgical treatments (lymphaticovenous anastomosis/lymphovenous bypass), and Vascularized Lymph Node Transfer.

Liposuction/Lipectomy (reductive)

Reductive surgery (liposuction/lipectomy) — evidence-supported scenarios

Liposuction + compression criteria: Patient has chronic, moderate-to-severe, non-pitting lymphedema (typically Stage II or III) of an extremity AND has had inadequate response to conservative therapies (compression/CCT/CDT).

Systematic reviews and HTAs report potential benefit (volume reduction, fewer infections, improved patient-reported outcomes) when liposuction is performed with controlled compression therapy, but evidence is low quality and procedures should be performed in specialist centers with multidisciplinary selection and lifelong compression per guidelines.

LVA and VLNT (therapeutic)

Physiological microsurgical procedures (LVA, VLNT) — evidence and selection

Microsurgical procedures general: Lymphaticovenous anastomosis (LVA) or vascularized lymph node transfer (VLNT) may be considered for patients with primary or secondary lymphedema who have not responded adequately to conservative therapy; choice of procedure depends on extremity, severity, and available donor/recipient anatomy.

Systematic reviews and meta-analyses report pooled clinical improvement (varying by procedure and extremity; e.g., LVA ~29% UEL, VLNT ~42% UEL) but studies are heterogeneous and generally low quality; guidelines note both procedures can reduce severity but are not curative and more high-quality comparative data are needed.

Preventive/Immediate Lymphatic Reconstruction (ILR/LYMPHA)

Preventive microsurgical procedures (ILR/LYMPHA) — when considered

Immediate lymphatic reconstruction (ILR/LYMPHA): Performed at the time of lymph node dissection (e.g., ALND or inguinal lymphadenectomy) with the intent to reduce incidence of secondary lymphedema; considered when technically feasible and after multidisciplinary evaluation.

Systematic reviews and meta-analyses report reduced incidence of lymphedema with ILR/LYMPHA (e.g., pooled reductions and risk ratios indicating substantial relative risk reduction), but evidence is low quality, often retrospective, and longer-term durability and generalizability remain uncertain; ongoing randomized trials are underway.

Coverage considerations / conditional coverage summary

Evidence and guideline summary supporting conditional coverage considerations:

Preventive ILR/LYMPHA for upper-extremity BCRL: Some systematic reviews and meta-analyses report reduced incidence of lymphedema after ALND when ILR/LYMPHA is performed (pooled incidences reported as low single-digit percentages and pooled risk reductions with NNTs reported), but the evidence is limited by small, heterogeneous, and mostly nonrandomized studies; randomized trials are ongoing.

See multiple systematic reviews and preliminary randomized trial reports; long-term durability and generalizability remain uncertain.

Preventive ILR/LYMPHA for lower-extremity lymphedema: Pooled analyses report lower limb ILR/PLS may reduce lymphedema rates after inguinal/ilioinguinal node dissection, but technical limitations (recipient veins) and heterogeneity of studies limit conclusions.

Evidence includes single-arm and cohort data with variable follow-up and diagnostic methods.

Therapeutic microsurgical procedures (LVA, VLNT): Consensus guidance (AAPS/ISL) and systematic reviews indicate LVA and VLNT can reduce severity of established lymphedema, particularly in earlier stages, but are not curative and higher-quality RCT evidence is limited.

This policy addresses surgical procedures proposed for the prevention or treatment of lymphedema, including but not limited to Axillary Reverse Mapping (ARM), Liposuction/Lipectomy, and microsurgical interventions such as lymphaticovenous anastomosis (LVA) and vascularized lymph node transfer (VLNT). These procedures are considered in the context of chronic primary or secondary lymphedema, typically after inadequate response to conservative therapy, and their safety and efficacy are evaluated against current evidence and guideline recommendations.

Reports have raised oncologic safety concerns for performing LVA at inguinal/groin sites following inguinal lymph node dissection (ILND) in melanoma or other skin malignancies; small retrospective series have described higher recurrence and worse recurrence-free or metastasis-free survival in some intervention cohorts, and these findings warrant caution when considering groin LVA in oncologic settings.

The National Institute for Health and Care Excellence (NICE) recommends that lymphovenous anastomosis (LVA) performed during axillary or inguinal node dissection be offered only with special arrangements for clinical governance, patient consent, audit or research, reflecting the need for structured oversight and additional study before routine adoption.

This Medical Policy is intended to assist in interpreting UnitedHealthcare standard benefit plans and is provided for informational purposes; it does not constitute medical advice. Coverage decisions must be made in accordance with applicable federal, state, or contractual plan terms, which govern in the event of any conflict.

Surgical procedures for the prevention or treatment of lymphedema are considered unproven and not medically necessary due to insufficient evidence of safety and/or efficacy; this statement applies to procedures including ARM, liposuction/lipectomy, lymphaticovenous anastomosis/bypass, and vascularized lymph node transfer.

The evidence base for many surgical lymphedema interventions is limited and heterogeneous; systematic reviews and health-technology assessments characterize options such as liposuction plus compression and microsurgical techniques as having potential but unproven benefit, particularly when study quality is low and outcomes are variable across patient populations and techniques.

A Cochrane review concluded there is currently insufficient high-quality evidence

Provider Actions, Prior Authorization, and Documentation

Prior Authorization
Prior Authorization and Code Reference (Pennsylvania)
Prior authorization is recommended to confirm patient selection and to document applicable codes for Pennsylvania. The applicable procedure and diagnosis codes are provided in the Applicable Codes section for reference only; listing does not imply coverage. Refer to Pennsylvania Exceptions, Pennsylvania Code, Title 55, Chapter 1101 for state‑specific requirements.
Check federal, state, and contractual benefit terms before authorization.
Reference the Applicable Codes list — inclusion does not guarantee coverage.

Denial Risk
Evidence Limitation May Trigger Denial
Surgical procedures for prevention or treatment of lymphedema are considered unproven and may be denied when evidence of safety and/or efficacy is insufficient. Lack of high‑quality evidence or inadequate documentation of medical necessity may lead to coverage denial.

Procedure and Billing Codes

Applicable CPT Codes (reference list)CPT

15830	Excision, excessive skin and subcutaneous tissue (includes lipectomy); abdomen, infraumbilical panniculectomy.
15832	Excision, excessive skin and subcutaneous tissue (includes lipectomy); thigh.
15833	Excision, excessive skin and subcutaneous tissue (includes lipectomy); leg.
15834	Excision, excessive skin and subcutaneous tissue (includes lipectomy); hip.
15835	Excision, excessive skin and subcutaneous tissue (includes lipectomy); buttock.
15836	Excision, excessive skin and subcutaneous tissue (includes lipectomy); arm.
15837	Excision, excessive skin and subcutaneous tissue (includes lipectomy); forearm or hand.
15838	Excision, excessive skin and subcutaneous tissue (includes lipectomy); submental fat pad.
15839	Excision, excessive skin and subcutaneous tissue (includes lipectomy); other area.
15847	Excision, excessive skin and subcutaneous tissue (includes lipectomy), abdomen (e.g., abdominoplasty) (includes umbilical transposition and fascial plication) (List separately in addition to code for primary procedure).

1–10 of 16
1/2

Definitions and Key Terms

inv-33: Axillary Reverse Mapping (ARM) — definition of ARM technique

DefinitionAxillary Reverse Mapping (ARM) is a technique that injects blue dye in the upper extremity to visualize and allow preservation of lymphatic channels and lymph nodes during axillary lymph node dissection.

PurposeIntended to identify and potentially preserve upper-extremity lymphatics during axillary lymph node surgery to reduce risk of postoperative lymphedema.

Source exampleDescribed in surgical definitions and cited literature (Jena).

inv-34: Liposuction/Lipectomy — definition of reductive procedure using vacuum suction

DefinitionLiposuction/Lipectomy is a procedure that uses vacuum suction to remove subcutaneous adipose tissue in certain anatomical areas.

Clinical context

Background and Evidence Context

Lymphedema is a chronic, progressive disorder resulting from damage to or maldevelopment of the lymphatic system, leading to accumulation of interstitial fluid and secondary hypertrophic adipose changes. First-line management is conservative therapy (e.g., complete decongestive therapy), and surgical approaches are investigational or reserved for selected patients refractory to conservative measures because long-term safety, durability, and comparative effectiveness remain inadequately established.

Policy Revision History

2025-12-01policy_revisionLatest

Policy updated: Description of Services, Clinical Evidence, and References sections were updated; previous policy version CS355PA.C archived.

2025-12-01policy_status_changeLatest

Policy marked as MODIFIED with an effective date of 2025-12-01; material changes and prior version archived.

Policy Summary

PayerUnitedHealthcare

PolicySurgery for the Prevention and Treatment of Lymphedema (for Pennsylvania Only)

Policy CodePolicy CS355PA.D

Change TypeUpdated clinical evidence, description of services, and references (material revision)

Effective DateDec 1, 2025

Next Review DateN/A

SourceLink

On This Page

Guidelines grade VLNT higher than LVA in some assessments; both require experienced surgical teams.

Liposuction for chronic non-pitting lymphedema: Guidelines and HTAs support specialized liposuction for chronic non-pitting/adipose-predominant lymphedema nonresponsive to conventional treatments when combined with lifelong compression; should be done in specialist centers after failure of conservative therapy.

NICE and ISL recommend multidisciplinary selection and specialist setting; procedure is not curative and relies on ongoing compression.

Quality and setting requirements: Guidelines recommend procedures be performed by experienced microsurgeons in high-volume or specialist centers with multidisciplinary teams; standardized staging, imaging (e.g., ICG), objective outcome measures, and longer-term follow-up data are needed.

NICE recommends special arrangements for governance, consent, audit or research for some procedures (e.g., LVA).

Examples include ARM, liposuction/lipectomy, microsurgical procedures (LVA, lymphovenous bypass, VLNT).
Denial may occur without adequate prior authorization or supporting documentation.

Note
Coverage Governed by Plan Terms
Coverage determinations must follow the terms of the member's benefit plan. If federal, state, or contractual requirements conflict with this policy, those requirements govern. Always verify plan‑specific coverage before approving services.
In the event of conflict, federal, state, or contractual requirements for benefit plan coverage govern.
UnitedHealthcare may apply additional tools (e.g., InterQual) when administering benefits.

Documentation Required
Suggested Documentation Elements
Document the clinical elements that support medical necessity and eligibility for surgical lymphedema procedures. Complete documentation increases the likelihood of appropriate prior authorization and accurate coverage decisions.
Stage of lymphedema (e.g., Stage II or III) and clinical signs (non‑pitting, fibrosclerotic changes).
Detailed history of conservative therapy (dates, duration, components of complete decongestive therapy [CDT] including manual lymphatic drainage, compression, exercise, skin care) and objective evidence of inadequate response.
Imaging and physiologic confirmation when used (e.g., ICG lymphangiography, bioimpedance, water displacement measurements) to demonstrate viable lymphatics or limb volume.
Multidisciplinary evaluation notes (team members, review date, rationale for surgery).
Operative plan with intended procedure(s), expected number of anastomoses (for LVA), and postoperative compression/rehabilitation plan.

Documentation Required
Provider Qualifications and Setting
Surgical lymphedema procedures should be performed in specialized settings by experienced teams. Provider qualifications and treatment setting impact risk and outcomes and should be documented.
Recommend performance at high‑volume centers with microsurgery training and established lymphedema programs.
Provider credentials: surgeon experience with microsurgical lymphatic procedures, team members (surgeon, lymphedema therapists, nursing, physiotherapy/OT).
Governance: institutional consent processes, audit/research arrangements, and long‑term follow up capability.

Prior Authorization
Conservative Therapy Required Prior to Surgery
Conservative therapy (complete decongestive therapy or equivalent multidisciplinary nonoperative care) must be attempted and documented prior to most surgical interventions for lymphedema. Surgery is typically considered only after documented inadequate response to optimized conservative care.
Complete decongestive therapy (CDT) elements: manual lymphatic drainage, compression garments/therapy, skin care, exercise — include duration and adherence.
For liposuction/lipectomy and many microsurgical interventions, document failure of conservative therapy before surgery; liposuction is generally reserved for Stage II–III non‑pitting lymphedema unresponsive to CDT.
NICE‑aligned expectation: liposuction should be used only for patients who have not responded to conventional treatments and in specialist centers; effectiveness relies on lifelong compression postoperatively.

Documentation Required
Documentation and Plan Alignment
Prior authorization decisions and clinical review should align with federal, state, and contractual plan requirements. Reviewers must confirm that documentation, governance arrangements, and provider qualifications meet plan standards before approving coverage.
Verify plan‑specific coverage rules and any Pennsylvania exceptions before approval.
Ensure multidisciplinary selection, documentation of failed conservative therapy, and appropriate center/provider qualifications are present in the record.

Used as a reductive surgical treatment for chronic, moderate-to-severe, non-pitting lymphedema (often Stage II or III) when conservative therapies have failed; typically combined with controlled compression therapy postoperatively.

Evidence noteSystematic reviews and HTAs report low-quality but suggestive evidence of limb volume reduction and reduced infections when combined with compression therapy.

inv-35: Lymphaticovenular/Lymphaticovenous Anastomosis (LVA) — definition of microsurgical connection

DefinitionLymphaticovenular/Lymphaticovenous Anastomosis (LVA) is a surgical procedure that connects small lymphatic vessels to adjacent venules to shunt excess lymphatic fluid.

MechanismMicrosurgical bypass intended to improve lymphatic drainage by providing lymphatic-to-venous outflow pathways.

Clinical considerationEvidence indicates effectiveness in reducing severity of lymphedema, particularly in earlier stages, but studies are heterogeneous and overall quality is limited.

inv-36: Vascularized Lymph Node Transfer (VLNT) — definition of transfer of skin, fat, and lymph nodes

DefinitionVascularized Lymph Node Transfer (VLNT) is a surgical procedure that transfers skin, fat, and lymph nodes (a lymph node–containing tissue flap) to the affected area for lymphatic reconstruction.

Donor/recipient detailsDonor flaps reported include groin, gastroepiploic/omental and other intra-abdominal or regional sites; outcomes vary by flap type and study.

Evidence noteSystematic reviews report limb volume reduction and fewer cellulitis episodes, but the evidence is generally low quality and heterogeneous.

inv-37: Lymphedema — definition of condition (build-up of fluid due to lymph system damage)

DefinitionLymphedema is the build-up of fluid in soft body tissues that occurs when the lymphatic system is damaged or blocked.

TypesPrimary lymphedema arises from congenital or developmental lymphatic abnormalities; secondary lymphedema results from trauma, infection, surgery, or radiation.

First-line managementConservative therapy (complete decongestive therapy: compression, skin care, manual lymphatic drainage, exercise) is the initial treatment modality.

inv-38: LVA (lymphaticovenous anastomosis) — additional definition and technical note on multiple anastomoses

DefinitionLVA (lymphaticovenous anastomosis) is a microsurgical bypass connecting lymphatic collectors to adjacent venules to improve lymphatic drainage.

Technical noteStudies report multiple anastomoses per patient (mean ~3.39 for upper extremity and ~4.50 for lower extremity in pooled analyses).

AdjunctsViable lymphatic vessels are often identified with ICG/near-infrared imaging; postoperative care commonly includes compression or manual drainage.

inv-39: VLNT (vascularized lymph node transfer) — description of donor sites and purpose

DescriptionVLNT involves transfer of lymph node–containing tissue flaps from donor sites such as the groin, gastroepiploic/omental region, submental area, jejunal mesentery, or mixed flaps to the affected limb or region to restore lymphatic function.

PurposeAims to restore lymphatic drainage, reduce limb volume, and decrease infection (cellulitis) frequency in selected patients with lymphedema.

Donor-site considerationsReported donor- and recipient-site complication rates are low in pooled analyses, but outcomes vary and evidence quality is limited.

inv-40: LYMPHA / ILR (immediate lymphatic reconstruction) — definition of preventive reconstruction performed at time of dissection

DefinitionLYMPHA / Immediate Lymphatic Reconstruction (ILR) is a preventive microsurgical reconstruction performed at the time of lymph node dissection (e.g., axillary lymph node dissection) to reduce the risk of postoperative secondary lymphedema.

Typical techniqueOften performed as intraoperative LVA (lymphaticovenous anastomosis) connecting transected lymphatics to nearby venules during the index lymphadenectomy.

Evidence summarySystematic reviews and meta-analyses report reduced incidence of secondary lymphedema with ILR/LYMPHA, but evidence is low quality and further RCTs are ongoing.

inv-41: Reductive surgery (liposuction/lipectomy) — definition emphasizing debulking of subcutaneous tissue with compression therapy

DefinitionReductive surgery (liposuction/lipectomy) is a debulking procedure that removes excess subcutaneous adipose tissue to reduce limb volume in chronic, non-pitting lymphedema, performed in conjunction with lifelong or long-term compression therapy.

IndicationGenerally reserved for later-stage (Stage II–III) fibrofatty, non-pitting lymphedema that is refractory to conservative therapies.

Postoperative managementRequires controlled compression therapy (CCT/CDT) postoperatively to maintain volume reduction and reduce recurrence.

inv-42: LYMPHA / ILR — alternate label and short definition (preventive microsurgical approach)

Alternate labelLYMPHA is also referred to as Immediate Lymphatic Reconstruction (ILR) or the Lymphatic Microsurgical Preventive Healing Approach.

Short definitionA preventive microsurgical approach performed during lymph node dissection to reconstruct lymphatic flow and reduce subsequent lymphedema risk.

Clinical noteEvidence shows lower incidence of lymphedema in many series, but findings are limited by study designs and heterogeneity.

inv-43: LVA — short definition (microsurgical anastomosis connecting lymphatics to venules)

Short definitionLVA is a microsurgical anastomosis connecting lymphatic vessels to venules to reduce lymphedema severity by improving lymphatic outflow.

Technical pointOften performed as multiple small anastomoses; best results reported in earlier-stage lymphedema and when performed by experienced microsurgeons.

Outcome summaryMeta-analyses report pooled clinical improvement but with high heterogeneity and limited high-quality RCT evidence.

inv-44: VLNT — short definition (microsurgical transfer of lymph node tissue)

Short definitionVLNT is a microsurgical transfer of lymph node–containing tissue (skin, fat, and lymph nodes) to an affected region to improve lymphatic drainage.

Clinical roleUsed therapeutically to reduce limb volume and cellulitis episodes in selected patients unresponsive to conservative therapy.

Evidence noteSystematic reviews indicate benefit in volume reduction and infection reduction, but evidence is generally low quality and heterogeneous.

inv-45: Liposuction (lymphatic liposuction) — definition focused on debulking in chronic non-pitting lymphedema

DefinitionLiposuction (lymphatic liposuction) is a debulking surgical technique to remove excess adipose tissue in chronic non-pitting lymphedema, typically followed by controlled compression therapy to maintain reductions.

Stage indicationMost often applied in later stages (Stage II–III) when fibroadipose tissue predominates and conservative therapy alone is ineffective.

Reported outcomesStudies report sustained volume reductions up to five years postoperatively and decreased infection rates in some series, though evidence quality varies.

inv-46: Lymphedema-related surgical procedures — list of procedures referenced across the policy (ARM, LVA, LYMPHA, VLNT, liposuction)

Procedures listedAxillary Reverse Mapping (ARM); Lymphaticovenular/Lymphaticovenous Anastomosis (LVA); LYMPHA / Immediate Lymphatic Reconstruction (ILR); Vascularized Lymph Node Transfer (VLNT); Liposuction/Lipectomy (lymphatic liposuction).

ContextThese procedures are referenced across the policy as surgical approaches for prevention or treatment of lymphedema with varying levels of supporting evidence and guideline endorsement.

Evidence summaryOverall, systematic reviews and HTAs note low-quality heterogeneous evidence supporting potential benefits in selected patients; conservative therapy remains first-line.